The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...

The US Food and Drug Administration (FDA) has approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, into biliary tract cancer (BTC).

The results of the baseline economic analysis by test strategy were as follows ... The results are not sensitive to varying levels of HER2 overexpression in the population, as shown for a US$ ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

SystImmune and Bristol Myers Squibb are testing a bispecific EGFR × HER3 ADC called BL-B01D1/BMS-986507 for various solid tumours. The School of Engineering (SOE) at Westlake University is ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in ...

Our QA program includes tumor analysis, nuclear score, tumor histological grade, IHC score and FISH score. Correlation with IHC and tumor histopathology and performing metrics is mandatory in order to ...

The availability of a simple immunohistochemical (IHC) test for HER2-low status is seen as critical to the successful rollout of Enhertu (trastuzumab deruxtecan) in this category of breast cancer ...